Masaki N, Yamagiwa Y, Shimbo T, Murata K, Korenaga M, Kanto T, Mizokami M; prefectural members contributing to the Japanese Interferon Database. Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study. BMC Public Health 2015;15:566. [PMID: 26088426 DOI: 10.1186/s12889-015-1891-2][Cited by in Crossref: 10][Cited by in F6Publishing: 6][Article Influence: 1.4][Reference Citation Analysis]
3
Ide K, Kawasaki Y, Yamada H, Masaki N. Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study. Drug Des Devel Ther 2016;10:1217-23. [PMID: 27042013 DOI: 10.2147/DDDT.S102458][Reference Citation Analysis]
4
Myers RP, Cooper C, Sherman M, Lalonde R, Witt-Sullivan H, Elkashab M, Harris P, Balshaw R, Usaty C, Marrotta PJ. Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). Can J Gastroenterol 2011;25:503-10. [PMID: 21912762 DOI: 10.1155/2011/698780][Cited by in Crossref: 4][Cited by in F6Publishing: 9][Article Influence: 0.4][Reference Citation Analysis]
